Essex Bio-Technology Interim Profit Plummets 32% on New China VAT Law

Essex Bio-Technology (1061.HK) announced a significant drop in its first-half earnings, with profit falling 32.2% year-on-year to approximately HK$111 million. The company attributed the sharp decline primarily to a new value-added tax (VAT) law in China that increased the tax burden on its core products.

First-Half Financials

In a filing, the company reported a broad-based decline in its key performance metrics for the interim period. Revenue was also affected, falling by double digits from the prior year.

• Revenue: Approximately HK$785 million, a decrease of 10.5% year-on-year.
• Profit: Approximately HK$111 million, a decrease of 32.2% year-on-year.
• Earnings Per Share: 19.53 HK cents.
• Interim Dividend: The board proposed an interim dividend of 5 HK cents per share.

Impact of Chinese Tax Reform

The company stated that the revenue decrease was a direct result of a new Chinese VAT law, which took retroactive effect from January 1. The regulation changed the tax treatment for wholesale sales of general biological products, including the company's Beifushu® and Beifuji® series.

Ad

Under the new rules, these products are now subject to the standard 13% VAT rate, consistent with other pharmaceuticals. Previously, wholesalers could opt for a simplified tax method at a 3% rate. Essex Bio-Technology noted that it could not pass this increased tax cost on to customers because its selling prices are fixed under China's centralized procurement system, and revenue is reported net of VAT.

Context for Investors

The results highlight the significant regulatory risk and margin pressure faced by pharmaceutical companies operating within China's state-controlled procurement framework. The inability to adjust prices in response to tax changes directly impacts profitability.

For investors, this underscores the vulnerability of the company's business model to policy shifts in its primary market. The market will be watching for the company's strategy to mitigate these margin pressures in future reporting periods. The declaration of an interim dividend may offer a degree of stability for shareholders despite the profit downturn.